SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Spurling, N.W.
Right arrow Articles by Carey, P.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spurling, N.W.
Right arrow Articles by Carey, P.F.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Medicines
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Dose Selection for Toxicity Studies: A Protocol for Determining the Maximum Repeatable Dose

N.W. Spurling

Development Division, Glaxo Group Research Ltd, Ware, Hertfordshire, SG12 ODP, UK

P.F. Carey

Development Division, Glaxo Group Research Ltd, Ware, Hertfordshire, SG12 ODP, UK

1 A three-stage protocol is described for a dose-ranging study which defines the maximum repeatable dose (MRD) and provides a preview of the toxicology of new, pharmacologically active, substances before commencing the first formal regulatory toxicity studies, usually of 2 or 4 weeks duration.

2 Additionally, a range of toxicokinetic (TK) data relevant to protocol design for formal studies is generated.

3 Stage A is a dose incrementation process in which the MRD is provisionally determined and basic TK values generated.

4 In stage B the animals are dosed daily for at least 7 d, the MRD is substantiated and a wider range of TK data obtained.

5 In stage C, each of the dose levels identified for a formal study is administered once to investigate the relationship of doses to TK data.

6 This protocol can be completed using as few as 24 rats or six dogs (or primates).

7 Selection of dose levels for the first formal studies can be greatly aided by the results of a well-designed dose-ranging study including TK data.

8 For particularly toxic substances, the findings of studies based on this protocol have frequently been sufficiently clear to warrant early termination of their development.

Human & Experimental Toxicology, Vol. 11, No. 6, 449-457 (1992)
DOI: 10.1177/096032719201100603
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement